ProCE Banner Activity

CONTINUATION-PV: 5-Yr Results of Ropeginterferon α-2b in Polycythemia Vera

Slideset Download
Conference Coverage
Durable hematocrit and molecular responses with long-term ropeginterferon α-2b therapy for patients with polycythemia vera.

Released: December 11, 2020

Expiration: December 10, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology